Rob Arnold

수석부사장 (EVP)


Consulting (Strategy Management & Regulatory), HEOR, Managed Markets, Market Access, Market Research, Research & Insights

"유럽, 북미, 아시아 전역에서 30년 이상 컨설팅 및 리더십 경력을 쌓은 Rob Arnold는 생명과학 분야에서 가장 까다로운 비즈니스 상황에 대한 창의적인 솔루션을 개발한 바 있습니다. R&D 포트폴리오, 생명공학 대기업의 방향 재설정 등 혁신과 전환 업무를 담당하고 있습니다.

Rob은 업계 포럼, 경영대학원, 전문 협회에서 생명과학 분야 전략에 대한 강연을 하고 있으며, 전문 논문도 여러 편 출간한 바 있습니다.

미국 다트머스대학교 에이머스턱비즈니스스쿨에서 MBA 학위를 받았고 캠브리지대학교에서 석사 학위를 받았습니다."

Articles by Rob Arnold

Reframing the Challenges of Access and ROI

Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see evidence of corporate responsibility, for which pharmaceuticals’ surrogate measure is access. While companies such as Novo Nordisk and UCB […]

WEBINAR: Sustainability in Pharma: Access and Financial Returns

In addition to the global disruption caused by COVID-19, pharma faces additional pressure to adopt digital technologies, transform long-standing business practices, and accelerate timelines to deliver value for HCPs and patients. Not to mention, the specialty pipeline continues to grow, but therapies for rare diseases are facing significant access challenges. In this webinar, EVERSANA’s Rob […]

How Do You Know Your Portfolio Process Is Adding Value?

In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage assets. SB publicly claimed that the review process had added $2.6 billion in value to the corporation. That team […]

Interested in scheduling a meeting or speaking event?


  • This field is for validation purposes and should be left unchanged.